M
Masato Nakaguro
Researcher at Nagoya University
Publications - 70
Citations - 839
Masato Nakaguro is an academic researcher from Nagoya University. The author has contributed to research in topics: Medicine & Adenocarcinoma. The author has an hindex of 11, co-authored 57 publications receiving 375 citations. Previous affiliations of Masato Nakaguro include Harvard University.
Papers
More filters
Proceedings ArticleDOI
Multi-scale Domain-adversarial Multiple-instance CNN for Cancer Subtype Classification with Unannotated Histopathological Images
Noriaki Hashimoto,Daisuke Fukushima,Ryoichi Koga,Yusuke Takagi,Kaho Ko,Kei Kohno,Masato Nakaguro,Shigeo Nakamura,Hidekata Hontani,Ichiro Takeuchi +9 more
TL;DR: Wang et al. as mentioned in this paper proposed a method for cancer subtype classification from histopathological images, which can automatically detect tumor-specific features in a given whole slide image (WSI), i.e., a large-sized image (typically 40,000x40,000 pixels) of an entire pathological tissue slide, which consists of cancer and non-cancer portions.
Posted Content
Multi-scale Domain-adversarial Multiple-instance CNN for Cancer Subtype Classification with Unannotated Histopathological Images
Noriaki Hashimoto,Daisuke Fukushima,Ryoichi Koga,Yusuke Takagi,Kaho Ko,Kei Kohno,Masato Nakaguro,Shigeo Nakamura,Hidekata Hontani,Ichiro Takeuchi +9 more
TL;DR: A new CNN-based cancer subtype classification method is developed by effectively combining multiple-instance, domain adversarial, and multi-scale learning frameworks in order to overcome practical difficulties.
Journal ArticleDOI
The Neuronal Differentiation Factor NeuroD1 Downregulates the Neuronal Repellent Factor Slit2 Expression and Promotes Cell Motility and Tumor Formation of Neuroblastoma
Peng Huang,Satoshi Kishida,Dongliang Cao,Yuko Murakami-Tonami,Ping Mu,Masato Nakaguro,Naoshi Koide,Ichiro Takeuchi,Akira Onishi,Kenji Kadomatsu +9 more
TL;DR: The findings establish the critical role of the neuronal differentiation factor NeuroD1 in neuroblastoma as well as its functional relationship with the neuronal repellent factor Slit2 and the functions identified for NeuroD 1 in cell motility and tumor sphere growth.
Journal ArticleDOI
Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.
Shogo Yamaguchi,Ryota Morimoto,Takahiro Okumura,Yuta Yamashita,Tomoaki Haga,Tasuku Kuwayama,Tsuyoshi Yokoi,Hiroaki Hiraiwa,Toru Kondo,Yuki Sugiura,Naoki Watanabe,Naoaki Kano,Kei Kohno,Kenji Fukaya,Akinori Sawamura,Kenji Yokota,Hideki Ishii,Masato Nakaguro,Masashi Akiyama,Toyoaki Murohara +19 more
TL;DR: This case showed that even if at a late phase, long-term use of immune checkpoint inhibitors might to lead immune-related adverse events including myocarditis, and nivolumab therapy rarely occurred at > 2 months use in clinical trials.
Journal ArticleDOI
Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment
Masato Nakaguro,Masato Nakaguro,Yuichiro Tada,William C. Faquin,Peter M. Sadow,Lori J. Wirth,Toshitaka Nagao +6 more
TL;DR: Several clinical studies have shown promising results using targeted therapy for androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2), and the latest version of the National Comprehensive Cancer Network guidelines recommends the evaluation of AR and HER2 status before treatment.